Age, race, CKD stage, serum 25D, plasma PTH level, serum Ca, serum P and comorbidities were put in comparison with a “none utility” average value of 20 because apatient profile was most likely, on average, to be treated with a vitamin D therapy based on a cumulative average part-worth level utility score above 20; a score lower than 20, resulted in no treatment. This evidence concerns the gene PTH and chronic kidney disease.